Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non‐Small Cell Lung Cancer

BACKGROUND. Tissue tumor mutational burden (TMB) has emerged as a potential biomarker predicting response to anti‐programmed cell death‐1 protein receptor (PD‐1)/programmed cell death‐1 protein ligand (PD‐L1) therapy, but few studies have explored using circulating tumor DNA (ctDNA) TMB in non‐small...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Chae, Young Kwang, Davis, Andrew A., Agte, Sarita, Pan, Alan, Simon, Nicholas I., Iams, Wade T., Cruz, Marcelo R., Tamragouri, Keerthi, Rhee, Kyunghoon, Mohindra, Nisha, Villaflor, Victoria, Park, Wungki, Lopes, Gilberto, Giles, Francis J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Immuno‐Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656496/
https://ncbi.nlm.nih.gov/pubmed/30867242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0433
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars